MOMO'S BREAKOUT BOARD

[AAAAMHIM]

$NSPX .0046 CAN IT RUN TO OVER $3?

Their drug mispargarin could replace chemotherapy.

$NSPX .0046?! WAS once $150 CANCER PATENT GRANTED NOT PR'ed. UNKNOWN. If you ever heard about $NSPX chances are you heard it from ME.

https://patents.justia.com/assignee/inspyr-therapeutics-inc

$NSPX HUGE Merger. NOT PR'D????
https://globenewswire.com/news-release/2017/09/13/1120305/0/en/Inspyr-Therapeutics-and-Lewis-and-Clark-Pharmaceuticals-Complete-Merger.html

Only 9 MILLION shares outstanding?

YOU guys KNOW how pharma stocks run from subs to $$$ ranges. $NSPX has a patent signed a $100 million private financing already received 25 million. Its A lotto for me but I like her. You see on the L2 after .02 is $200, THIN. Only reason its down at this mouth watering price is because it is VERY UNKNOWN. Won't be unknown for long

This is a little sloppy write up. Just little items I connected together. Trying to simplify the DD.

$NSPX Secures Patent on Methods of Producing Cancer Targeting

Inspyr Therapeutics Secures Patent on Methods of Producing Cancer Targeting CompoundsPharmaceutical | Tue 19 Dec 2017Alexandria, Dec. 19 -- Inspyr Therapeutics has secured a patent on methods of producing cancer targeting compounds. Lynch John K, Hutchison Jeff, #$%$ Xiong and Kunnen Kevin developed the invention. The patent application number is 15/232,599. The International Patent Classification codes are C07D 307/93 (20060101), C07C 227/16 (2..

"INSPYR THERAPEUTICS AND LEWIS AND CLARK PHARMACEUTICALS MERGE"

"Lewis & Clark Pharma: We have deep expertise in the synthesis, analysis, and early stage development of adenosine receptor-based compounds, with a focus on A2A and A2B antagonists, and A2A agonists. Our proprietary compounds are highly potent and selective, and – most importantly, have molecular properties that enable enhanced distribution in tissue and penetration of human skin – and the opportunity for novel therapies that could address a broad range of large, chronic, underserved diseases:

A2A/A2B antagonists for a range of tumors, as a mono- or combination therapy, including:

Solid tumors, e.g., breast, colorectal, melanoma, lung, prostate, bladder

Hematological malignancies, e.g., multiple myelomas, acute lymphocyte leukemia"

From the annual report from fiscal year ending December 31, 2016: Our major focus for the next twelve to eighteen months is the (i) development of a clinical protocol for and enrollment into a dose optimization trial of single-agent mipsagargin followed by a clinical trial in patients with advanced HCC, (ii) completion of the non-clinical study of mipsagargin in combination with Nexavar® in liver tumor models (iii) development of a Phase 1b clinical protocol of mipsagargin in combination with Nexavar® in patients with Nexavar® naïve HCC in anticipation of positive non-clinical data, (iv) completion of a nonclinical study of mipsagargin in combination with paclitaxel and in combination with DC101 (Cyramza surrogate antibody) in gastric cancer tumor models, (v) ongoing business development discussions with potential development partners, (vi) evaluation of mipsagargin (single agent and in combination with standard of care) in nonclinical models of other solid tumor types that express PSMA, (vii) evaluate our PSMA-peptide prodrug technology with new linkers and new payloads in non-clinical models, and (viii) explore collaborations utilizing mipsagargin in new, non-clinical solid tumor models with leading researchers in the oncology field.

Proceeds will be used to advance Inspyr’s clinical development plans and provide for working capital needs. The Company’s entry into the Milost Equity Subscription Agreement Financing Facility (MESA) and the initial tranche of funding is subject to required approvals, final documentation, and customary closing conditions.

“We are pleased to have reached an agreement on the key investment terms, the first step in securing a solid foundation of capital for Inspyr for the next several years,” said Peter Grebow, Ph.D., Chairman of Inspyr Therapeutics.

“We are pleased to be a financial partner to Inspyr and look forward to closing the transaction promptly,” said Egerton Forster, Milost Global Inc. Co-found

NSPX RECENTLY SECURED
100M in financing from private equity firm, the needle is moving in the right direction.

"Well...I see that they have started a couple trials involving treatment with sorafenib with mipsigargin as an adjuvant therapy.
Hmmmmmmmmmmmmmmmmm...they say they are looking for a synergistic effect from the combo. The non pre clinical trial will be used on folks with advanced HCC, so they are looking for arresting progression of the disease. Mipsigargin was a lot better at arresting progression than sorafenib's 2 months. Perhaps together they can arrest progression for a year or more. I suspect that even with progression arrested, many folks will die as a result of the damage the cancer has already caused.

Hey...the company is moving forward again. Cheers for the new year!!!"

Can $NSPX run over $3? Its a cancer pharma stock with patents. 1 succesful trial away from $100+ imo. You know how these pharmas go. Hit or miss.

NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX